Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Eledon Pharmaceuticals is a biotech company focused on developing immunology-based therapies targeting the CD40 Ligand pathway. Its lead candidate, tegoprubart, is an anti-CD40L antibody designed to prevent organ transplant rejection, treat autoimmune diseases, and address neurodegenerative conditions like ALS. The company advances its products through clinical trials, leveraging proprietary IP, and collaborates with research institutions to improve transplant outcomes and neuroinflammation management.
This description was generated via AI from an annual report. Updated about 1 year ago.